These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15122748)

  • 1. Screening in liver disease: report of an AASLD clinical workshop.
    Adams PC; Arthur MJ; Boyer TD; DeLeve LD; Di Bisceglie AM; Hall M; Levin TR; Provenzale D; Seeff L
    Hepatology; 2004 May; 39(5):1204-12. PubMed ID: 15122748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening of colorectal cancer.
    Winawer SJ
    Surg Oncol Clin N Am; 2005 Oct; 14(4):699-722. PubMed ID: 16226687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of chronic liver disease: costs and benefits.
    Quinn PG; Johnston DE
    Gastroenterologist; 1997 Mar; 5(1):58-77. PubMed ID: 9074920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report.
    Naghavi M; Falk E; Hecht HS; Jamieson MJ; Kaul S; Berman D; Fayad Z; Budoff MJ; Rumberger J; Naqvi TZ; Shaw LJ; Faergeman O; Cohn J; Bahr R; Koenig W; Demirovic J; Arking D; Herrera VL; Badimon J; Goldstein JA; Rudy Y; Airaksinen J; Schwartz RS; Riley WA; Mendes RA; Douglas P; Shah PK;
    Am J Cardiol; 2006 Jul; 98(2A):2H-15H. PubMed ID: 16843744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing on international application of evidence-based guidelines.
    Hayashino Y; Shimbo T; Tsujii S; Ishii H; Kondo H; Nakamura T; Nagata-Kobayashi S; Fukui T
    Int J Cardiol; 2007 May; 118(1):88-96. PubMed ID: 16949690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence.
    Inadomi JM
    J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S198-204. PubMed ID: 19120898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk assessment for prevention of morbidity and mortality: lessons for pressure ulcer prevention.
    Reynolds TM
    J Tissue Viability; 2008 Nov; 17(4):115-20. PubMed ID: 19061825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention and screening. Part II: Critical appraisal of articles on screening.
    Soares I; Carneiro AV
    Rev Port Cardiol; 2003 Jan; 22(1):117-30. PubMed ID: 12712815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for disease, cost-effectiveness, and guidelines.
    Meyer DL
    Prim Care; 1995 Dec; 22(4):591-9. PubMed ID: 8668731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multidisciplinary management of gastrointestinal cancer. Colorectal cancer screening.
    Winawer SJ
    Best Pract Res Clin Gastroenterol; 2007; 21(6):1031-48. PubMed ID: 18070702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.
    Okonkwo QL; Draisma G; der Kinderen A; Brown ML; de Koning HJ
    J Natl Cancer Inst; 2008 Sep; 100(18):1290-300. PubMed ID: 18780864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.
    Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
    Eur J Public Health; 2009 Jun; 19(3):245-53. PubMed ID: 19196737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of prescreening versus empirical vaccination for hepatitis A in Egyptian children with chronic liver disease.
    El-Karaksy H; El-Sayed R; El-Raziky M; El-Koofy N; Mansour S
    East Mediterr Health J; 2008; 14(4):804-9. PubMed ID: 19166163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing and testing a cost-assessment tool for cancer screening programs.
    Subramanian S; Ekwueme DU; Gardner JG; Trogdon J
    Am J Prev Med; 2009 Sep; 37(3):242-7. PubMed ID: 19666160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guideline implementation for breast healthcare in low- and middle-income countries: early detection resource allocation.
    Yip CH; Smith RA; Anderson BO; Miller AB; Thomas DB; Ang ES; Caffarella RS; Corbex M; Kreps GL; McTiernan A;
    Cancer; 2008 Oct; 113(8 Suppl):2244-56. PubMed ID: 18837017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines.
    Anderson BO; Shyyan R; Eniu A; Smith RA; Yip CH; Bese NS; Chow LW; Masood S; Ramsey SD; Carlson RW
    Breast J; 2006; 12 Suppl 1():S3-15. PubMed ID: 16430397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status and future role of health screening.
    North AF
    South Med J; 1977 Oct; 70(10):1232-6. PubMed ID: 410110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report.
    Comeau AM; Accurso FJ; White TB; Campbell PW; Hoffman G; Parad RB; Wilfond BS; Rosenfeld M; Sontag MK; Massie J; Farrell PM; O'Sullivan BP;
    Pediatrics; 2007 Feb; 119(2):e495-518. PubMed ID: 17272609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of screening strategies for Gonorrhea among females in private sector care.
    Bernstein KT; Mehta SD; Rompalo AM; Erbelding EJ
    Obstet Gynecol; 2006 Apr; 107(4):813-21. PubMed ID: 16582117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Health economics analysis of colorectal screening].
    Boncz I; Sebestyén A; Dózsa C; Pál M; Sándor J; Palásti J; Betlehem J; Ember I
    Magy Onkol; 2004; 48(2):111-5. PubMed ID: 15351803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.